Effect of SGLT-2 Inhibitors on Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes Mellitus and MASLD. UOC 2026, No. 1. https://doi.org/10.57033/RSSPMCE-2026-00022.